A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

Inclusion Criteria:

- Has at least one lesion that can be evaluated by RECIST

- Has fully recovered from all toxicities due to the following:

- Has a life expectancy of at least 3 months.

- Negative serum pregnancy test.

Exclusion Criteria:

- Is pregnant or breastfeeding.

- Is a woman of childbearing potential unwilling to use an approved, effective means of
contraception according to the institution's standards.

- Is a man of childbearing potential unwilling to use an approved, effective means of
contraception according to the institution's standards.

- Has a history of brain metastases, unless adequately treated and without radiologic
evidence of progressive disease for at least 3 months after completion of therapy.

- Has a known active infection.